Send to

Choose Destination
Curr Opin Mol Ther. 2006 Oct;8(5):461-7.

Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia.

Author information

Royal Perth Hospital, Department of Core Clinical Pathology and Biochemistry, PathWest Laboratory Medicine WA, Wellington Street, GPO Box X2213, Perth, WA 6847, Australia.


ISIS-301012 is an antisense oligonucleotide inhibitor of apolipoprotein B-100, which is being developed by Isis Pharmaceuticals Inc for the potential treatment of hypercholesterolemia. A subcutaneous injectable formulation is currently undergoing phase 11 clinical trials, while phase I trials are underway with an oral formulation of the drug.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center